Published

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Translational psychiatry
Date: 2025-11-13
Source: PubMed
DOI: 10.1038/s41398-025-03693-w
PubMed: 41257994

Authors

Martens MAG Cunha BG Erritzoe D Nutt D Carhart-Harris R Harmer CJ

Watch author

Derived topics and classifications

psilocybin Depression Mechanism of Action Emotional Processing Clinical Trial Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.2025-11-13

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01 Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19 Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative MechanismsClinicalTrials.gov · 2024-10-24 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidenceZenodo (CERN European Organization for Nuclear Research) · 2026-01-26